CYTK: Mizuho Raises Target
Mizuho maintains outperform rating on Cytokinetics and raises price target to $118
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.
Mizuho maintains outperform rating on Cytokinetics and raises price target to $118
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.